Law360, New York (March 30, 2011, 5:28 PM ET) -- Apotex Corp. on Tuesday agreed to hold off on manufacturing a generic version of Lovaza until 2015 to resolve Norwegian pharmaceutical company Pronova BioPharma Norge AS' patent infringement claims over the triglyceride-lowering drug.
In separate stipulations of dismissal without prejudice, the parties agreed to voluntarily drop Pronova's two infringement suits that were scheduled to begin the first phase of trial in the U.S. District Court for the District of Delaware on Tuesday, with each party bearing its own attorneys' fees and costs.
Although the stipulation did...
Pronova, Apotex Strike Deal Over Generic Lovaza
To view the full article, take a free trial now.
